Media stories about Acceleron Pharma (NASDAQ:XLRN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.4952629718296 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions (finance.yahoo.com)
- Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire (finance.yahoo.com)
- Corporate News Blog – Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195 (finance.yahoo.com)
- Acceleron Pharma Inc. (XLRN) PT Set at $51.00 by Credit Suisse Group (americanbankingnews.com)
- $3.37 Million in Sales Expected for Acceleron Pharma Inc. (XLRN) This Quarter (americanbankingnews.com)
Shares of Acceleron Pharma (NASDAQ XLRN) opened at $36.97 on Friday. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $40.35.
Several research analysts have weighed in on XLRN shares. Credit Suisse Group set a $35.00 price target on Acceleron Pharma and gave the company a “buy” rating in a report on Saturday, August 5th. HC Wainwright boosted their price target on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Finally, BidaskClub downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $44.88.
In other Acceleron Pharma news, SVP Christopher Rovaldi sold 14,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $537,740.00. Following the completion of the transaction, the senior vice president now directly owns 28,232 shares of the company’s stock, valued at approximately $1,084,391.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total transaction of $614,560.00. Following the completion of the transaction, the chief financial officer now directly owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,513 shares of company stock valued at $2,055,485. 3.90% of the stock is owned by insiders.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
What are top analysts saying about Acceleron Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma Inc. and related companies.